Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers

24 Aug 2023

Abstract excerpt

BACKGROUND: Patient-derived glioma stem-like cells (GSCs) have become the gold-standard in neuro-oncological research; however, it remains to be established whether loss of in situ microenvironment affects the clinically-predictive value of this model. We implemented a GSC monolayer system to investigate in situ-in vitro molecular correspondence and the relationship between in vitro and patient response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Glioma Diagnosis and Treatment
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37620410
DOI: 10.1038/s41416-023-02402-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkersPMID 37620410Read ↗

Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere modelsSemantic proximity Read ↗

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastomaSemantic proximity Read ↗

Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses.Semantic proximity Read ↗

Exploring Responses of Glioblastoma Patient-Derived Cell Cultures to Drugs Reveals New Therapeutic OpportunitiesSemantic proximity Read ↗

Gliamimic: A Longitudinal, Multimodal in Vitro Platform for Evaluating Glioblastoma Treatment Response and Relapse in Patient-derived Organoids or SpheroidsSemantic proximity Read ↗

Digital transcriptome profiling of normal and glioblastoma-derived neural stem cells identifies genes associated with patient survivalSemantic proximity Read ↗

Transitioning pre-clinical glioblastoma models to clinical settings with biomarkers identified in 3D cell-based models: A systematic scoping reviewSemantic proximity Read ↗

A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem CellsSemantic proximity Read ↗

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastomaSemantic proximity Read ↗

Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patientsSemantic proximity Read ↗

Characterization of EGFR-reprogrammable temozolomide-resistant cells in a model of glioblastomaSemantic proximity Read ↗

Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.